OrbiMed announces closing of next venture capital fund with $950M
OrbiMed's newest funding is planned to go toward companies focusing on oncology, central nervous system disease and gene editing.
OrbiMed's newest funding is planned to go toward companies focusing on oncology, central nervous system disease and gene editing.